Researchers at CSIR’s Centre for Cellular and Molecular Biology have identified the biological circuit that allows Cryptococcus neoformans — a fungus responsible for roughly one in five AIDS-related deaths worldwide — to balloon into giant “Titan cells” that evade the immune system, opening a new line of attack against a disease with few treatment options.
For two decades, mycologists have known that Cryptococcus neoformans — a fungus that causes a form of meningitis responsible for a substantial share of AIDS-related deaths globally — can transform some of its cells into enormous “Titan cells,” up to ten times the normal size, that are harder for the immune system to engulf and destroy. What has been missing is a mechanistic explanation for how the fungus decides to make this transformation. Researchers at the Hyderabad-based CSIR-Centre for Cellular and Molecular Biology (CCMB), led by Dr Sriram Varahan, have now identified the biological circuit behind it, in a study published in the journal Genetics (Oxford Academic) this month.
The core finding overturns a simplifying assumption in fungal biology: that metabolism — the machinery that converts nutrients into usable energy — is a purely supportive process, separate from the signalling systems that govern a cell’s behavioural decisions. The CCMB team’s work shows that in C. neoformans, metabolism is itself part of the decision-making system.
How the circuit works
The researchers found that efficient glucose metabolism in the fungus helps maintain a stable balance of calcium inside the cell. Calcium acts as a fast-acting molecular messenger, relaying information between different parts of the cell. When calcium levels are properly maintained, they activate calcineurin — a signalling pathway already known to be essential for the fungus’s ability to survive the hostile conditions inside a human body, including the elevated body temperature and immune assault it encounters after infection. The new study establishes, for the first time, a direct causal chain linking energy metabolism, calcium signalling and calcineurin activation, showing that these three systems function as a single coordinated network governing Titan cell formation rather than as independent processes.
“We uncovered an unexpected biological connection between the fungus’s energy hub and one of its most important survival pathways,” Varahan said, describing the findings. “Our findings show that metabolism is not merely supplying fuel, it is actively controlling the cellular signals that allow the fungus to transform into titan cells.”
Why the target matters
Titan cells are not a curiosity of laboratory fungal biology — they are central to how C. neoformans survives inside a human host and causes disease. Their larger size makes them physically harder for immune phagocytes to engulf, and evidence from prior research links Titan cell formation to increased drug resistance and altered exposure of molecular patterns that the immune system uses to recognise pathogens. A fungus that successfully titanises is, in practical terms, a fungus that is harder for the body — and for antifungal drugs — to clear.
C. neoformans causes cryptococcal meningitis, a leading cause of death among people with advanced HIV/AIDS, particularly in regions with high HIV burden and limited access to early antiretroviral therapy. Existing antifungal treatments target the fungus directly, but resistance and limited drug options remain a persistent clinical problem. By identifying the specific molecular vulnerability that enables titanisation, the CCMB study points toward a fundamentally different therapeutic strategy: rather than trying to kill the fungus outright, future drugs could instead aim to block the metabolism–calcium–calcineurin circuit and prevent it from ever forming the enlarged, immune-evading cells in the first place.
What is not yet established
This is a mechanistic biology finding, not a treatment. The study identifies the circuit and demonstrates its role through genetic and pharmacological perturbation in laboratory conditions; it does not yet report a drug candidate, an animal model of infection outcomes, or any clinical testing. Translating a validated molecular target into an actual therapy — even one that repurposes existing calcineurin-pathway inhibitors, several of which already exist for other medical uses — will require substantial further work, including confirming that blocking the circuit in a living, infected host actually reduces disease severity rather than simply preventing titanisation in isolation. The calcineurin pathway itself is already an established drug target in fungal disease more broadly, which may shorten this path relative to a therapy requiring an entirely novel mechanism, but that remains to be demonstrated rather than assumed.
Why it matters
Cryptococcal disease remains a major and under-addressed cause of mortality among immunocompromised patients globally, and India carries a significant share of the world’s HIV burden alongside limited access to newer antifungal agents in public health settings. A homegrown mechanistic discovery of this kind — identifying a specific, targetable vulnerability in one of the fungus’s core survival strategies — is scientifically significant in its own right and consistent with CCMB’s standing as one of India’s leading centres for molecular and cellular biology research. It also illustrates a broader principle increasingly central to infectious disease research: that a pathogen’s metabolism can be as valid and important a drug target as the toxins or virulence factors it produces directly.
Anusha Singh
Key facts
- Discovery: a biological circuit linking glucose metabolism, calcium signalling and calcineurin activation controls Titan cell formation in Cryptococcus neoformans
- Titan cells are up to ten times normal fungal cell size and help the fungus evade the immune system
- Published in Genetics (Oxford Academic), August 2026; research led by Dr Sriram Varahan, CSIR-Centre for Cellular and Molecular Biology, Hyderabad
- C. neoformans causes cryptococcal meningitis, linked to roughly one in five AIDS-related deaths globally
- Finding is mechanistic; no drug candidate or clinical testing has yet resulted from it
